When a patient first begins to take antidepressants, there is actually a chance that person may commit suicide within the first two weeks — it’s known as medication-induced suicide.
The risk increases during this recovery period, and scientists have not known why in the past. According to the Max Planck Institute of Psychiatry, 59 percent of patients committed suicide within two weeks of initial treatment, and 8 percent experienced the adverse effects of medication when they first began taking them.
The company Sundance Diagnostics plans to enter a licensing agreement with the Max Planck Institute of Psychiatry to bring a new suicidality test into the market. The suicidality test would be able to identify a person’s suicide risk based on certain gene markers.
Read the full, original story: New ‘Suicidality’ Test Predicts Antidepressant-Induced Suicide Risk In Patients
